{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:32:36Z","timestamp":1773660756609,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,10,7]],"date-time":"2010-10-07T00:00:00Z","timestamp":1286409600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s00403-010-1085-9","type":"journal-article","created":{"date-parts":[[2010,10,6]],"date-time":"2010-10-06T08:33:52Z","timestamp":1286354032000},"page":"35-40","source":"Crossref","is-referenced-by-count":2,"title":["Plasma TM2-PK levels in mycosis fungoides patients"],"prefix":"10.1007","volume":"303","author":[{"given":"Asl\u0131","family":"Hapa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcl","family":"Erkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcl\u015fen","family":"Has\u00e7elik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilara","family":"Pekta\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umut","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,7]]},"reference":[{"key":"1085_CR1","first-page":"1689","volume":"30","author":"C Benesch","year":"2010","unstructured":"Benesch C, Schneider C, Voelker HU, Kapp M, Caffier H, Krockenberger M et al (2010) The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer. Anticancer Res 30:1689\u20131694","journal-title":"Anticancer Res"},{"key":"1085_CR2","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0190-9622(99)70079-4","volume":"40","author":"E Diamandidou","year":"1999","unstructured":"Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R (1999) Prognostic factor analysis in mycosis fungoides\/Sezary sendromu. J Am Acad Dermatol 40:914\u2013924","journal-title":"J Am Acad Dermatol"},{"key":"1085_CR3","first-page":"3153","volume":"17","author":"E Eigenbrodt","year":"1997","unstructured":"Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G (1997) Quantification of tumor type m2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res 17:3153\u20133156","journal-title":"Anticancer Res"},{"key":"1085_CR4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0147-0272(90)90017-K","volume":"14","author":"RT Hoppe","year":"1990","unstructured":"Hoppe RT, Woods GS, Abel EA (1990) Mycosis fungoides and the Sezary syndrome: pathology, staging and, treatment. Curr Probl Cancer 14:295\u2013371","journal-title":"Curr Probl Cancer"},{"key":"1085_CR5","first-page":"2753","volume":"19","author":"F Hugo","year":"1999","unstructured":"Hugo F, Fischer G, Eigenbrodt E (1999) Quantification of tumor type M2 pyruvate kinase in serum and plasma. Anticancer Res 19:2753\u20132758","journal-title":"Anticancer Res"},{"key":"1085_CR6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13277-009-0010-3","volume":"31","author":"Y Kumar","year":"2010","unstructured":"Kumar Y, Mazurek S, Yang S, Failing K, Winslet M, Fuller B et al (2010) In vivo factors influencing tumour M2-pyruvate kinase level in human pancreatic cell lines. Tumour Biol 31:69\u201377","journal-title":"Tumour Biol"},{"key":"1085_CR7","first-page":"375","volume":"30","author":"S Landt","year":"2010","unstructured":"Landt S, Jeschke S, Koeninger A, Thomas A, Heusner T, Korlach S et al (2010) Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancer. Anticancer Res 30:375\u2013381","journal-title":"Anticancer Res"},{"key":"1085_CR8","first-page":"5077","volume":"20","author":"D L\u00fcftner","year":"2000","unstructured":"L\u00fcftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD et al (2000) Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 20:5077\u20135082","journal-title":"Anticancer Res"},{"key":"1085_CR9","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.semcancer.2005.04.009","volume":"15","author":"S Mazurek","year":"2005","unstructured":"Mazurek S, Boschek B, Hugo F, Eigenbrodt E (2005) Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15:300\u2013308","journal-title":"Semin Cancer Biol"},{"issue":"2A","key":"1085_CR10","first-page":"1149","volume":"23","author":"S Mazurek","year":"2003","unstructured":"Mazurek S, Eigenbrodt E (2003) The tumor metabolome. Anticancer Res 23(2A):1149\u20131154","journal-title":"Anticancer Res"},{"key":"1085_CR11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1042\/bj3560247","volume":"356","author":"S Mazurek","year":"2001","unstructured":"Mazurek S, Zwerschke E, Jansen-D\u00fcrr P, Eigenbrodt E (2001) Effects of the human papillioma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic enzyme complex. Biochem J 356:247\u2013256","journal-title":"Biochem J"},{"key":"1085_CR12","doi-asserted-by":"crossref","first-page":"513 e1","DOI":"10.1016\/j.urology.2010.04.034","volume":"76","author":"B Nisman","year":"2010","unstructured":"Nisman B, Yutkin V, Nechushtan H, Gofrit ON, Peretz T, Gronowitz S et al (2010) Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy. Urology 76:513 e1\u2013513 e6","journal-title":"Urology"},{"key":"1085_CR13","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"E Olsen","year":"2007","unstructured":"Olsen E, Vonderheid E, Pimpinelli N, Williemze R, Kim Y, Knobler R et al (2007) Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of the research and treatment of cancer (EORTC). Blood 110:1713\u20131722","journal-title":"Blood"},{"key":"1085_CR14","first-page":"1135","volume":"23","author":"GM Oremek","year":"2003","unstructured":"Oremek GM, Rox ST, Mitrou P, Sapoutzis N, Sauer-Eppel H (2003) Tumor M2-PK levels in haematological malignancies. Anticancer Res 23:1135\u20131138","journal-title":"Anticancer Res"},{"key":"1085_CR15","first-page":"2599","volume":"19","author":"GM Oremek","year":"1999","unstructured":"Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH (1999) The pyruvate kinase isoenzyme Tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Res 19:2599\u20132602","journal-title":"Anticancer Res"},{"key":"1085_CR16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2133.2005.06649.x","volume":"153","author":"R Ponti","year":"2005","unstructured":"Ponti R, Quaglino P, Novelli M, Fierro MT, Comessatti A, Peroni A et al (2005) T cell receptor gamma gene rearrangements by multiplex polymerase chain reaction\/heteroduplex analysis in patients with cutaneous T-cell lymphoma(mycosis fungoides\/Sezary syndrome) and benign inflammatory disease:correlation with clinical, histological and immunophenotypical findings. Br J Dermatol 153:565\u2013573","journal-title":"Br J Dermatol"},{"key":"1085_CR17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0304-3835(02)00720-6","volume":"193","author":"J Schneider","year":"2003","unstructured":"Schneider J, Neu K, Velcovsky HG, Morr H, Eigenbrodt E (2003) Tumor M2-pyruvate kinase in the follow-up of inoperable lung cancer patients: a pilot study. Cancer Lett 193:91\u201398","journal-title":"Cancer Lett"},{"key":"1085_CR18","first-page":"4961","volume":"20","author":"G Schulze","year":"2000","unstructured":"Schulze G (2000) The tumor marker tumor M2-PK: an application in the diagnosis of gasrointestinal cancer. Anticancer Res 20:4961\u20134964","journal-title":"Anticancer Res"},{"key":"1085_CR19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1515\/CCLM.2006.006","volume":"44","author":"P Staib","year":"2006","unstructured":"Staib P, Hoffmann M, Schink\u00f6the T (2006) Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors. Clin Chem Lab Med 44:28\u201331","journal-title":"Clin Chem Lab Med"},{"key":"1085_CR20","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.3748\/wjg.v12.i43.7007","volume":"12","author":"C Tonus","year":"2006","unstructured":"Tonus C, Neupert G, Sellinger M (2006) Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J Gastroenterol 12:7007\u20137011","journal-title":"World J Gastroenterol"},{"key":"1085_CR21","first-page":"2583","volume":"19","author":"HW Wechsel","year":"1999","unstructured":"Wechsel HW, Petri E, Bichler KH, Feil G (1999) Marker for renal cell carcinoma: dimeric form of pyruvate kinase type M2. Anticancer Res 19:2583\u20132590","journal-title":"Anticancer Res"},{"key":"1085_CR22","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Williemze","year":"2005","unstructured":"Williemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Steven H et al (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768\u20133785","journal-title":"Blood"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-010-1085-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-010-1085-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-010-1085-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T13:37:43Z","timestamp":1559050663000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-010-1085-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,7]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["1085"],"URL":"https:\/\/doi.org\/10.1007\/s00403-010-1085-9","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,7]]}}}